Neuraxis Inc — Cash Flow (NYSE:NRXS) | MetaTrader

Open full chart

Financials

Overview Relevé Statistics

Quarterly Annual

Cash from operating activities -6.69 M-6.1 M-6.43 M -6.43 M Cash from investing activities -71.78 K-27.78 K-131.15 K -131.15 K Cash from financing activities 6.59 M9.74 M7.83 M 7.83 M Free cash flow -6.77 M-6.13 M-6.56 M -6.46 M

Nouvelles

NeurAxis, Inc. (NRXS) Q4 2025 Earnings Call Transcript

The Zacks Analyst Blog Meta, Bank of America, The Procter & Gamble, Espey and NeurAxis

Top Stock Reports for Meta, Bank of America & Procter & Gamble

NRXS Stock Declines Post Q3 Earnings Despite Continued Revenue Growth

L’action de Neuraxis augmente après l’autorisation de la FDA pour le traitement de la douleur abdominale

Neuraxis stock rises after FDA clearance for abdominal pain treatment

Neuraxis reçoit l’autorisation de la FDA pour son dispositif PENFS et élargit son offre sur le marché

Neuraxis publie des résultats financiers préliminaires du T3 2025 avec une perte d’exploitation de 2,1 millions €

Neuraxis reports preliminary Q3 2025 financial results with $2.1 million operating loss

The Zacks Analyst Blog Highlights Alphabet, IBM, Merck, SandRidge Energy and NeurAxis

Top Research Reports for Alphabet, IBM & Merck

Neuraxis enters $3.3 million at-the-market equity offering agreement